公开(公告)号：US20220392603A1

公开(公告)日：2022-12-08

申请号：US17834332

申请日：2022-06-07

Applicant: INSULET CORPORATION

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG

IPC: G16H20/30 ,  A61B5/00 ,  A61M5/172 ,  G16H20/17

Abstract: Described are techniques, processes, devices, computer-readable media that enable provision of an indication of whether it is safe for a person with diabetes to participate in exercise while using a wearable drug delivery system. A processor may receive or obtain physiological data related to a condition of a wearer of the wearable drug delivery system and by evaluating an exercise model that uses inputs related to the physiological data to make the determination of whether it is safe to exercise and output an exercise safety signal. Modifications to the wearer's medication treatment plan and other actions may be based on an outputted exercise safety signal.

公开(公告)号：US20210236730A1

公开(公告)日：2021-08-05

申请号：US17166072

申请日：2021-02-03

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Steven CARDINALI

IPC: A61M5/172 ,  G16H20/17 ,  G16H10/60 ,  G16H20/30 ,  G16H50/20

Abstract: In an automated insulin delivery device, fuzzy logic may be applied to the responding to the possibility of a user taking additional action that may affect the blood glucose concentration. Fuzzy sets may be defined for empirically derived different likelihoods of the user taking such additional action based on correlated factors. A membership function may be provided for each fuzzy set. The membership function may provide a probability of membership in the set based on a parameter. Each fuzzy set may have a response that is reflective of the likelihood of additional user action associated with the fuzzy set. The responses by the AID device to each of these cases may reflect the probability of each such case occurring as evidenced by empirical data.

公开(公告)号：US20210187197A1

公开(公告)日：2021-06-24

申请号：US17123378

申请日：2020-12-16

Applicant: Insulet Corporation

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

Abstract: Disclosed are devices, a system, methods and computer-readable medium products that provide techniques to implement functionality to determine when to softened upper bounds of drug delivery and how much to soften the upper bound. Future blood glucose measurement values may be predicted by calculating deviations between predicted blood glucose measurement values and additional blood glucose measurement values. A gain parameter may be determined for use with a model of predicting a user's blood glucose measurement values and determining future drug dosages. Safety constraints may be determined based on an evaluation of missing blood glucose measurement values. In addition, safety constraints may be determined based on an evaluation of a user's increased interaction with an automatic drug delivery device. A bolus uncertainty metric to determine an amount of insulin to be provided in a bolus dosage in response to a bolus request may be calculated.

公开(公告)号：US20210170104A1

公开(公告)日：2021-06-10

申请号：US17112314

申请日：2020-12-04

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Steven CARDINALI ,  Jason O'CONNOR ,  Eric BENJAMIN ,  Ian MCLAUGHLIN ,  David NAZZARO ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G16H40/67 ,  G16H20/17 ,  G16H50/70 ,  G16H10/60 ,  G16H50/30 ,  G16H40/40 ,  G16H20/60 ,  G01N33/49

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US20250132007A1

公开(公告)日：2025-04-24

申请号：US18909496

申请日：2024-10-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Yibin ZHENG ,  Jason O’CONNOR

IPC: G16H20/17 ,  A61M5/142 ,  A61M5/172

Abstract: A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.

公开(公告)号：US20240252753A1

公开(公告)日：2024-08-01

申请号：US18633816

申请日：2024-04-12

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Steven CARDINALI ,  Jason O'CONNOR ,  Eric BENJAMIN ,  Ian MCLAUGHLIN ,  David NAZZARO ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70

CPC classification number: A61M5/1723 ,  A61M5/14248 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US20240252751A1

公开(公告)日：2024-08-01

申请号：US18629121

申请日：2024-04-08

Applicant: INSULET CORPORATION

Inventor： Jason O’CONNOR ,  Joon Bok LEE ,  Trang LY ,  Todd VIENNEAU ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/28 ,  A61M5/14248 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201 ,  A61M2230/63

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

公开(公告)号：US20240157053A1

公开(公告)日：2024-05-16

申请号：US18498275

申请日：2023-10-31

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Yibin ZHENG ,  Jason O’CONNOR ,  James CAUSEY ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  G16H20/17 ,  A61M2005/1401 ,  A61M2005/1726

Abstract: Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.

公开(公告)号：US20240009392A1

公开(公告)日：2024-01-11

申请号：US18350223

申请日：2023-07-11

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Joshua WILLIAMS ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2202/0486

Abstract: Exemplary embodiments may determine anticipated basal insulin delivery action to a user from an insulin delivery device over a future time window. Indications of the anticipated basal insulin delivery action over the future time window may be output to the user. The exemplary embodiments may determine the anticipated basal insulin delivery action over the future time window based on a rate of change (ROC) of glucose level of the user by the insulin delivery device, a most recent (“current”) glucose level for the user and insulin on board (IOB) for the user. The exemplary embodiments may also determine whether the user is likely to experience a undesired high glucose level (e.g., hyperglycemia) and/or an undesired low glucose level (e.g., hypoglycemia) during the future time window. The exemplary embodiments may output recommendations based on the projected glucose levels of the user over the future time window.

公开(公告)号：US20230330337A1

公开(公告)日：2023-10-19

申请号：US18300201

申请日：2023-04-13

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Ashutosh ZADE ,  Jonathan HARDY

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2202/0486

Abstract: Disclosed herein are various embodiments comprising methods to propose or modify a basal profile of a user, wherein the basal profile is delivered by an automatic drug delivery system operating in manual mode or is administered manually by the user. Suggestions of initial basal profiles or modifications to existing basal profiles may be based on previous glucose control outcomes or previous insulin delivery as recorded by the automatic drug delivery system.